Poster
Reductions in Polypharmacy for Patients With Indolent Systemic Mastocytosis on Avapritinib
Author
Cem Akin
Condition
Indolent Systemic Mastocytosis
Drug target
KIT D816V
Drug moa
Tyrosine kinase inhibitor
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-AAAAI-2024-Avapritinib-Indolent-Systemic-Mastocytosis-Reductions-Polypharmacy-Burden-Poster.pdf
20 organizations
1 product
Product
AvapritinibOrganization
Guy’s & St Thomas’ NHS Foundation TrustOrganization
University of UtahOrganization
University of AntwerpOrganization
Erasmus Medical CenterOrganization
Brigham and Women’s HospitalOrganization
University of MichiganOrganization
Huntsman Cancer InstituteOrganization
Centre Hospitalier Universitaire de ToulouseOrganization
University Medical Center GroningenOrganization
University Hospital MannheimOrganization
St Michael’s HospitalOrganization
Dana–Farber Cancer InstituteOrganization
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of MedicineOrganization
Blueprint Medicines